Another study in NSCLC patients treated with anti-PD-1 and anti-PD-L1 antibodies, suggested that patients receiving corticosteroids at baseline (when treatment is initiated) fare worse than those not on corticosteroids [59]. Here, PDCD1 is linked to non-small cell lung carcinoma.